



JANE CHEN

Partner-Shanghai

+86 21 2208 1166

jie.chen@fangdalaw.com

PRACTICE AREA

MS. CHEN IS A CORPORATE PARTNER IN OUR SHANGHAI OFFICE, SPECIALIZING IN CAPITAL MARKETS, PRIVATE EQUITY, AND CORPORATE AND M&A.

Education

- East China University of Political Science and Law, School of Law, LL.B.

Professional Qualification

- Admitted to practice in the PRC

Work Language

- Chinese
- English

Professional Background

- Ms. Chen joined the Shanghai Office of Fangda Partners in 2022. She is a member of the Securities Business Research Committee of the Shanghai Bar Association.

REPRESENTATIVE MATTERS AND CASES

Domestic Financing

- Acted for Lead Show (603272.SH) as issuer's counsel in its A-share IPO
- Acted for Huaertai (001217.SZ) as issuer's counsel in its A-share IPO
- Acted for Chenguang New Materials (605399.SH) as issuer's counsel in its A-share IPO
- Acted for Sanyou Medical (688085.SH) as issuer's counsel in its A-share IPO
- Acted for Hainan Mining (601969.SH) as issuer's counsel in its A-share IPO
- Acted for Universal Scientific (601231.SH) as issuer's counsel in its A-share IPO
- Acted for WUS Printed (002463.SZ) as issuer's counsel in its A-share IPO
- Acted for MicuRx Pharmaceutical (Registered) as issuer's counsel in its A-share IPO
- Acted for Universal Scientific (601231.SH) as issuer's counsel in its private share placement
- Acted for Yunnan Salt and Chemical (002053.SZ) as issuer's counsel in its private share placement
- Acted for Anjoy Foods (603345.SZ) as issuer's counsel in its convertible debt projects
- Acted for NovelBeam (688677.SH) as underwriter's counsel in its A-share IPO
- Acted for Endovascular (688016.SH) as underwriter's counsel in its A-share IPO
- Acted for HCFA (688320.SH) as underwriter's counsel in its A-share IPO

Overseas Financing

- Acted for Tuya Smart (NYSE: TUYA) as PRC counsel in its NYSE IPO
- Acted for Junshi Bio (1877.HK) as PRC counsel in its H-share IPO and its H-share follow-on offerings
- Acted for Fosun Pharma (2196.HK) as PRC counsel in its H-share IPO and its H-share follow-on offerings
- Acted for Sinopharm (1099.HK) as PRC counsel in its H-share IPO and its H-share follow-on offerings
- Acted for Gland Pharma (NSE: GLAD) as PRC counsel in its spin-off from Fosun Pharma and its listing in India
- Acted for Wuxi Apttec (603259.SH and 2359.HK) as underwriters' counsel in its A-share and H-share offering
- Acted for Henlius (2696.HK) as underwriters' counsel in its H-share IPO
- Acted for Ark Bio as underwriters' counsel in its H-share IPO

Others

- Advised Endovascular, Sanyou Medical, Junshi Bio, Anjoy Foods, Techmation, Haid Group, WUS, and Fosun Pharma on general corporate matters
- Represented CSC Shipping in issuing shares and paying cash to purchase Boya Technology and in raising matching funds
- Represented China Trade Logistics in issuing shares and paying cash to purchase Zhongte Logistics and in raising matching funds
- Represented Anjing Food in its acquisition of Hongye Aquatic
- Represented Akcome Group in its acquisitions of MSH Insurance Company in France and Zhenjing Clinic in the US
- Represented Monfali in its acquisition of all shares in Ojiahua, a listed company in Malaysia
- Represented China Trade Logistics in its cash acquisition of Dexiang Logistics
- Represented Hongxun Technology in its investment in Dongguan Zhiyin
- Represented Sanyou Medical in its acquisition of Shuimu Tianpeng
- Represented Haida Group in its acquisitions of Depot and other companies
- Represented American Warburg Pincus in its investments in Sida Restaurant Group, King Mother and Baby Products Retailer, and Red Star Macalline
- Represented Linxin Capital in its investments in Canxin, Core Long March and Junxin Electronics
- Represented Juntong Capital in its investments in Hongsoft Technology, Lanqi Technology and Broadcom Technology
- Represented True Gold Fund in its investment in Shangxun Information
- Represented Ping An Trust in its investment in Xi'an Ruilian
- Represented Huagai Capital and Junlian Capital in their investments in the Series C financing of Motorcomm and in the Series A+ and Series B financing of MicuRx Pharmaceutical, a leading mother and baby e-commerce company
- Represented Xinhua Capital in its investments in Henlius and other companies

Publications/Articles

- Participated in the compilation of "Practice of Securities Law Practice for Lawyers" published by Law Press·China

Professional Affiliations

- Member of the Securities Business Research Committee of the Shanghai Bar Association
 - Member of the Lujiazui-Shanghai No.2 Branch Committee of The Revolutionary Committee of the Chinese Kuomintang
-